Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 26

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 26
---
 vote of a majority in voting power of the shares of stock of the Company which are present or represented by proxy at the 2025 Annual Meeting and entitled to vote thereon is required to approve the foregoing resolution.

Board Recommendation

The Board recommends that the stockholders vote “FOR” the approval, on a non-binding, advisory basis, of the compensation paid to the Company’s named executive officers.

<div align='center'>COMPENSATION AND OTHER INFORMATION CONCERNING DIRECTORS AND OFFICERS</div>

Our compensation philosophy is to offer our executive officers compensation and benefits that are competitive and meet our goals of attracting, retaining and motivating highly skilled management, which is necessary to achieve our financial and strategic objectives and create long-term value for our stockholders. We believe the levels of compensation we provide should be competitive, reasonable and appropriate for our business needs and circumstances. Our Board of Directors periodically uses benchmark compensation studies in determining compensation elements and levels. The principal elements of our executive compensation program have to date included base salary, annual bonus opportunity and long-term equity compensation in the form of restricted stock units and stock options. We believe successful long-term Company performance is more critical to enhancing stockholder value than short-term results. For this reason and to conserve cash and better align the interests of management and our stockholders, we emphasize long-term performance-based equity compensation over base annual salaries.

The following table sets forth information concerning the compensation earned by the individual that served as our principal executive officer during 2024, our two most highly compensated executive officers other than the individual who served as our principal executive officer during 2024, and up to two additional individuals for whom disclosure would have been provided but for the fact that such individual was not serving as an executive officer at the end of the last completed fiscal year (collectively, the “named executive officers”):

| 21 |

2024 Summary Compensation Table

| Name and PrincipalPosition                             
 Alexander Tokman                                       
 Chief Executive Officer (since August 13, 2024)        
 Francois Michelon                                      |     | Year 
 2024 
 2024 |     | Salary ($) | 114,231 
 202,126 |     | Option Awards ($)(1) |     954 
       - | (3) |     | Non-equity Incentive Plan Compensation ($) | - 
 - |     | All Other Compensation ($) | 100,000 
 112,524 | (3)(4) 
 (2)(5) |     | Total ($) | 215,